Member Info for EmeraldCarrots

Than Cellbxheath by market cap. That is truly astonishing, is it not. This new "Master Services Contract" is going to mean Cellbxheath will be incredibly busy in a few months. No doubt they will be weighing up the increased workload to see what new staffing levels they will need. One wonders what Myriad Genetics makes of all this, Immatics and Illumina too no doubt. All very exciting. They will be advertising for new stall very soon I think!

Astrazenica market cap £210 Billion.

Cellbxhealth market cap £25 million.

=============

Astra 8,400 times as big.

.

Throwing toys out of the pram springs to mind. It makes no sense not talking to the USA as they have cut off the money supply. Every day their situation gets worse. They should have done a deal a few weeks back. Now there may not be one on offer at all.

All IMHO.

A complimentary way of detecting stage 3 and 4 cancer. Hang on a min! Parsortix could help with that, could it not!!!!!!!!!? Have a word with Colin about it please. LOL! We will see if we can fit you in. He's probably heard about your Company already.

All IMHO.

The machines is the EU. Frustrating or what! Hope he gets them to buck their ideas up as we need sales to Countries in the EU as well. It never seems to get mentioned!!

All IMHO.

The machines is the EU. Frustrating or what! These clowns need to do something!

All IMHO.

Hmm. That would cause a few issues.

I see it. The sp is now up 4.65%. I bought more earlier too. In fact 2 lots.

No ramping. Just the facts.

Ramping is inflating good news beyond reason in my view.

I just want to make potential investors aware.

The RNS below about the "Master Services Agreement" is the best news Cellbxhealth could have.

One presumes all the parts of Astrazenica ***throughout the World*** will be notified that they have done a deal so Cellbxhealth can be employed to analyse CTC's from participants in cancer drug trials. I wonder what the response will be? This offers the chance to have blood tested before, during and after a cancer drug trial to analyse any circulating tumor cells!! What would they NOT want that?? I mean why????? These trials are already very expensive. You would want the maximum feedback from your drug's effect would you not?? Unless you are a bit daft I suppose!

https://www.lse.co.uk/rns/CLBX/msa-with-global-pharmaceutical-company-egbtxodxy71zuq7.html

Moment?

==========================

AI Overview

AstraZeneca is currently running over 240 global clinical trials across their entire R&D pipeline, with a significant and growing focus on their AstraZeneca Oncology Portfolio and Pipeline. Their broader pipeline features 186 total projects, which includes dozens of active clinical trials evaluating immunotherapies, antibody-drug conjugates, and targeted therapies.

====================

Astrazenica market cap £210 Billion.

Cellbxhealth market cap £25 million.

=============

Astra 8,400 times as big.

Cellbxheath has less than 60 employees at the moment. That is going to increase a lot, although in the past it was envisaged that Parsortix labs might be set up by other Companies offering the analysis of CTC's that have been caught by the Parsortix machine.

All IMHO.

Https://investors.immatics.com/news-releases/news-release-details/immatics-presents-data-ima401-magea48-bispecific-2026-asco

Cancer drug trials, and those are only the ones that involve cancer that is suspected, or is spreading. The "Master Services Agreement" enables the people organising these trials to more easily get Cellbxhealth on board. The agreement affectively IMHO has not only secured the future of Cellbxhealth but the future is looking very, very good. No doubt other massive Plc's will want similar. No doubt Cellbxhealth will want top dollar from any other Plc's. Remember Parsortix is unique. It can catch live, intact, uncontaminated CTC's for ANY sort of analysis.

All IMHO.

Also they have over 100 cancer drug trials on at the moment that involve matasticised cancer. All of these could be monitored using the Parsortix machine. ALL OF THEM.................

All IMHO.

So by that measure Astrazenica are TEN THOUSAND times bigger than Cellbxhealth. Also they have over 100 cancer drug trials on at the moment that involve matasticised cancer. All of these could be monitored using the Parsortix machine. ALL OF THEM.................

All IMHO.

As IRGC takes control. Unfortunately, if true, the 90m population won't be at all happy with that one.............

https://www.mirror.co.uk/news/world-news/iran-war-trump-ceasefire-live-37227616

Back down from his key demands. The only 2 options he has are to simply wait while Iran crumbles further (and the Iran Government hopes their system won't collapse due to no money), or go again trying to speed up an agreement.. I suspect he will wait another few weeks at least. Meanwhile the strait is being cleared of mines, all be it slowly. If the Clerics want to stay in power they had better do a deal. Then at least they will have something to build on. If their regime collapses they will be leaving the Country asap in fear of their lives I think.

All IMHO.

This is at Minimum news of Astronomical proportions to Cellbxhealth. At maximum there are no words. It is off the scale. The RNS means:-

1. One of the biggest pharma Companies in the World (market cap over £210 Billion) want to analyse cancer circulating tumor cells (CTC's) on a far bigger scale than previous. Note Astra have been working closely with

2. Astra were working closely with Cellbxhealth last year and did two contracts:-

a) Androgen Receptor (AR) Assay: Developed a £670,000 circulating tumour cell (CTC) test to detect AR status in prostate cancer patients using the Parsortix system.

b) DNA Damage Response (DDR) Assay: Developed and validated a novel DDR methodology for micronuclei detection in CTCs to measure how well therapies target various cancers.

? Are Astra intending to use these tests in upcoming cancer drug trials?

3. What do Astra have in mind for the future as far as analysing CTC's is concerned?

- Do they intend to employ Cellbxhealth in every cancer drug trial in future that involves cancer that is possibly about to or is already metastasising.

- This makes perfect sense to me at least. Why on Earth would you NOT want to analyse CTC's (if there are any) to get the maximum amount of information from your very expensive cancer drug trial? I don't know how this works at Astra. However surely if a trial involves cancer that is possibly about to or is already metastasising the people organising the trial MUST want the CTC's analysed. I honestly can't see why they would not,.

4. All the other massive Pharma Plc's will want similar deals............... and will have to pay top dollar as far as I am concerned. They must have been half asleep the past few years not to have seen this coming.

5. Bid for Cellbxhealth even more likely IMHO.

https://www.lse.co.uk/rns/CLBX/msa-with-global-pharmaceutical-company-egbtxodxy71zuq7.html

All IMHO.

Cancer are Astrazenica doing at the moment?

AI Overview

AstraZeneca has over 100 ongoing clinical trials investigating treatments for metastasized and advanced cancers. Because drug portfolios are incredibly dynamic—with new studies launching and others completing globally every week—the exact count of active trials fluctuates constantly.

========================

We would be too busy with half a dozen! I wonder whether even the Directors at Cellbxhealth realise even if only a tiny number of Astra cancer drug trials (worldwide) want the CTC's analysed before, during and after the workload would be many multiples of the current. They could look at expanding staff numbers at Guildford to the max and then look into subbing the work out to other Companies?

All IMHO.

And I suspect it will improve from that in the coming weeks. The agreement with Astrazeneca has secured the future and no doubt other top 10 pharma Plc's will follow. Parsortix is unique in the World...........

All IMHO.

Will want to know WHY Astrazeneca now see themselves working with us on so many new contracts a general one was needed that covers all future contracts. Obviously if they did not think there will be numerous new contracts they would not bother with this "Master Services" one. I just hope they intend to use Cellbxhealth in ****ALL of their future cancer drug trials where the cancer has metastasized****. I think this very likely. Why would you not want to analyse the CTC's before, during and after treatment to see the effect? Only an idiot would not.

All IMHO.